SmallCapVoice: Advanced Medical Isotope (ADMD) Obtains Exclusive License for Injectable Radiogel for High-Dose Interstitial Radiation Therapy
Advanced Medical Isotope, a company engaged in the production and distribution of medical isotopes, has obtained an exclusive license to eight patents for injectable radiogel technology for use in high-dose radiation therapy. The license was granted by Battelle pursuant to an option between Battelle and AMIC announced in February 2011.
The Agreement grants AMIC an exclusive license to make, have made, use and sell a radiogel system including an injectable, water-based biodegradable polymer that delivers Yttrium-90 microspheres directly into tumor tissues. The solution warms to body temperature quickly after injection and then polymerizes into a lattice that traps the Yttrium-90 microspheres in place. High-energy beta particles from Yttrium-90 efficiently irradiate cancer cells within the targeted volume but very little radiation escapes. This feature maximizes the overall radiation dose to cancer cells while minimizing radiation exposure and associated side-effects in nearby normal tissues.
The injectable radiogel may also be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors, and pancreatic cancer. Levels of activity may be accelerated to treat radiation-resistant solid tumors that may not respond well to conventional external-beam therapy.
Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 microspheres and the radiogel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost.
Dr. Robert Schenter, AMIC’s Chief Scientific Officer, stated, “AMIC continues to develop the Yttrium-90 radiogel line with Pacific Northwest National Laboratory, operated by Battelle. We believe that this product optimizes treatment of radiation-resistant tumors in vivo. We expect the radiogel to become a therapeutic agent that provides physicians with the ability to effectively treat tumors that cannot be removed surgically or that cannot be treated by any other means.”
According to AMIC Chairman and Chief Executive Officer James C. Katzaroff, the primary advantages of licensing these Yttrium-90 radiogels are multifold:
This treatment provides the ability to deliver a highly localized radiation therapy without irradiating nearby normal tissues – thereby achieving desired high therapeutic indices. We are able to provide dose homogeneity within a solid tumor. Because Yttrium-90 is a beta emitter, there is improved radiation safety for hospital personnel who prepare and handle the product.
Let us hear your thoughts below: